This activity minimizes blood vessel dilation and nerve inflammation. The FDA has approved three CGRP inhibitors, collectively called gepants, for the acute treatment of migraine with or without aura: ...

Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...

Headaches, including migraines, are common. It is estimated that one out of every six Americans experiences migraines or severe headaches. Over-the-counter (OTC) medications for migraines are ...

Pharma giant AbbVie has been taken to task by the FDA for running an ad for one of its migraine drugs, featuring tennis ... In the ad for oral CGRP inhibitor Ubrelvy (ubrogepant), Williams is ...

Headaches, including migraines, are common. It is estimated that one out of every six Americans experiences migraines or ...

The key to stopping a migraine episode is early recognition and treatment. Treatments are more likely to be successful when you start them early rather than waiting to see if the symptoms get worse.

Now, she’s on disability because of her migraine. Irons has tried so many migraine medications she’s lost count — but none have helped for long. Even a few of the much-touted new drugs that ...

Axsome Therapeutics' Q3 2024 earnings report shows a revenue beat with $104.8m. See why I think selling AXSM stock on any ...

5-hydroxytriptamine is a key mediator in the pathogenesis of migraine and thus 5-HT 1-receptor agonists are the principal drugs for acute migraine therapy. There are three classes of drugs for ...

ABBV's third-quarter 2024 earnings and sales beat estimates. The company increases the EPS guidance on encouraging product ...